Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or relapsed B cell lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma|Refractory B-Cell Non-Hodgkin Lymphoma
DRUG: Selicrelumab|DRUG: Atezolizumab
optimal dose of intratumoral Selicrelumab in combination with flat doses of Atezolizumab IV, 21 days (1 cycle)
complete metabolic response rate (CMR), 2 months|complete metabolic response rate (CMR), 4 months|complete metabolic response rate (CMR), 8 months|complete metabolic response rate (CMR), 13 months|overall metabolic response rate (OMR), 2 months|overall metabolic response rate (OMR), 4 months|overall metabolic response rate (OMR), 8 months|overall metabolic response rate (OMR), 13 months|Best overall metabolic response (BOMR), 4 months|duration of response (DOR), 2 years|progression free survival (PFS), 2 years|overall survival (OS), 2 years|Number of serious adverse event (SAE), 16 months
This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or relapsed B cell lymphoma